Biometric Monitoring Technologies: The V3 Framework

The Foundation Of Determining Fit-For-Purpose For Biometric Monitoring Technologies (Biomets)

This peer-reviewed publication in npj Digital Medicine introduces the V3 framework, verification, analytical validation, and clinical validation, the foundational method for determining whether a Biometric Monitoring Technology (BioMeT) is fit-for-purpose in clinical trials. Co-authored by Koneksa’s Elena Izmailova alongside the Digital Medicine Society (DiMe), the paper establishes a shared vocabulary and best practices for evaluating digital measurement tools such as wearables and sensors used to generate digital biomarkers and digital endpoints.

Digital medicine draws together engineering, clinical science, data science, biostatistics, regulatory science, and patient advocacy. That diversity is valuable, but it has created confusion: the same term is often used to mean different things, and different terms are used for the same concept. The authors clarify this core terminology without introducing unnecessary new language, giving sponsors, technology developers, and regulators a common evidence base for evaluating biometric monitoring technologies.

What Is the V3 Framework?

V3 is a three-component evaluation framework that answers a single question: is this digital measurement fit-for-purpose? The three stages are verification, analytical validation, and clinical validation. Each stage builds on the last, and all three are required before a BioMeT can be trusted to generate reliable digital endpoints in a clinical study.

Verification, Analytical Validation, and Clinical Validation Explained

Verification evaluates whether the sensor and hardware capture sample-level data accurately and as intended, confirming performance at the level of the raw signal. Analytical validation evaluates the algorithm that converts that sample-level data into a physiological or behavioral metric, confirming the processed measure is accurate and reliable. Clinical validation confirms that the BioMeT acceptably identifies, measures, or predicts a meaningful clinical, biological, physical, or functional outcome in the intended population and context of use.

Why Fit-for-Purpose Evaluation Matters for Clinical Trials

Applying V3 gives clinical trial teams a defensible, regulatory-aligned basis for selecting biometric monitoring technologies and the digital endpoints they produce. A common framework improves communication across disciplines, strengthens the evidence base for digital measurement, and makes it easier to demonstrate that wearables and connected sensors are ready for use in drug development and decentralized trials.

Together, verification, analytical validation, and clinical validation form the foundation for trustworthy digital biomarkers, helping researchers adopt digital measurement tools with confidence and improving how outcomes are captured in modern clinical research.